INNOVATION
MEETS
EXPERTISE
ABOUT US
Coeptis Holdings, Inc., together with its subsidiaries including Coeptis Therapeutics, Inc., Coeptis Pharmaceuticals, Inc., and SNAP Biosciences, Inc. (collectively “Coeptis”), is a biopharmaceutical and technology company developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases that have the potential to disrupt conventional treatment paradigms and improve patient outcomes.
Coeptis’ therapeutic portfolio is highlighted by assets licensed from Deverra Therapeutics, including an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. Coeptis is also developing a universal, multi-antigen CAR technology licensed from the University of Pittsburgh (SNAP-CAR).
The Company is headquartered in Wexford, PA.
LEADERSHIP TEAM
Management has demonstrated a track record of acquiring and developing novel therapies.

Dave Mehalick
Chairman, President and Chief Executive Officer
Mr. Mehalick is a successful executive with a career spanning over 30 years across a variety of industries including life sciences, technology, financial services, military contracting, entertainment, and consumer products.
READ MORE
Mr. Mehalick’s career has allowed him deep immersion into all facets of executive management notably mergers and acquisitions, corporate finance, C- Suite management, product development and licensing, partnerships, product commercialization, and corporate communications.
He has assisted and managed several organizations towards successful investor monetization across all aspects of company evolution resulting in billions of dollars in transactions and financings. Currently, Mr. Mehalick is our Chairman, Chief Executive Officer and President, and one of our co-founders. He has been involved in several companies in a variety of positions and functions prior to Coeptis spanning many different industries.
Mr. Mehalick began his career in the financial services industry in the wealth management area before transitioning to investment banking in the early 2000’s. He held positions of Vice President and Senior Vice President at multiple firms notably First Union Capital Markets, Gruntal and Co. and Ferris Baker Watts. He then began working earnestly with companies to assist them in all aspects of growth.
He was a founding partner in American Defense Systems, a military contractor designing lightweight antiballistic armor and hardening systems for transportation and solid structures. After procuring several military contracts, the company grew revenues to a point that they became public on the AMEX stock exchange.
Throughout his career Mr. Mehalick was involved in numerous similar situations either in a management or consultant role to allow strong returns for shareholders via acquisitions or public strategies.

Brian Cogley
Chief Financial Officer
Brian Cogley is a senior-level financial executive with over 15 years of experience in corporate finance and accounting across a variety of industries, including life sciences, pharmaceuticals, financial services, and manufacturing.
READ MORE
Prior to joining Coeptis Therapeutics, Mr. Cogley was a Senior Manager in the Accounting Advisory practice at CFGI, LLC., where he served pharmaceutical and financial services clients in technical accounting implementations and execution. In this role, he led financial operations for client companies and successfully executed various financial projects while performing multiple interim management roles.
Formerly, Mr. Cogley worked as the Vice President of Finance & Accounting at NexTier Bank, after holding previous roles as Global Cash Manager, Senior Accountant, Financial Analyst and Senior Audit Associate across the finance industry, including at KPMG, a “Big 4” accounting firm.
In Mr. Cogley’s varied career experience, he developed expertise in financial planning, reporting and variance analysis, as well as in asset and liability management, handling cash, investments, derivatives and debt portfolios for efficient use of company funds.
A forward-thinker with problem-solving skills and enthusiasm, Mr. Cogley’s leadership of teams has resulted in innovative thinking and tangible results.
Mr. Cogley holds a bachelor’s degree in accounting and a Master of Business Administration with a concentration in finance from Duquesne University.

Christine Sheehy
VP of Compliance and Corporate Secretary
Christine Sheehy is a pharmaceutical business leader with over 25 years of experience, including globally commercializing drug products and working in development of targeted therapeutics including cell and gene therapies.
READ MORE
Ms. Sheehy was Senior Vice-President of Operations for Kadmon Pharmaceuticals, leading the global supply chain, distribution, and IT organizations. She was a founding employee of start-up pharmaceutical company Three Rivers Pharmaceuticals, which was acquired by Kadmon Pharmaceuticals in 2010. During that time, she launched branded and generic products in the U.S., leading the operational business.
Globally, Ms. Sheehy has executed international supply and distribution partnerships in Europe and Asia. Prior to Three Rivers Pharmaceuticals, Ms. Sheehy held various roles ranging from business and finance consulting to financial management.
Strategically minded, with a strong ability to understand all aspects of the business, her leadership skills have been developed by working substantially in start-ups and early-stage companies.
Additionally, over the past 15 years Ms. Sheehy has held board of director and advisory positions for multiple industry organizations, and she holds a bachelor’s degree in accounting from Penn State University.

Dan Yerace
Director and Vice President of Operations
Dan Yerace is a co-founder of Coeptis and serves as the Vice President of Operations. Mr. Yerace has over fifteen years of experience in the pharmaceutical and biotech industries and is a key strategist responsible for supply chain management, business development, portfolio management, and corporate strategy.
READ MORE
Mr. Yerace has broad operational experience and has held leadership positions in procurement, global supply chain management, operations, and business development for small private firms and fortune 500 multi-national corporations.
Prior to joining Coeptis, Mr. Yerace served as Senior Director of Global Supply Chain and Commercial Business Development for Kadmon Pharmaceuticals.
Mr. Yerace holds a bachelor’s degree in economics, and a masters of business administration from Waynesburg University.
SCIENTIFIC ADVISORY BOARD
Our Scientific Advisory Board is comprised of leading scientists in cell and gene therapy.

Evren Alici M.D., PhD.
Dr. Alici is the Head of the Gene and Cell Therapy Group, Division of Hematology, Department of Medicine, Karolinska Institutet, Karolinska University Hospital.
READ MORE
As a senior researcher and group leader in Hematology at KI, Department of Medicine, he also serves as co-director of NextGenNK, an international Competence Center for the development of next-generation NK cell-based cancer immunotherapies based at KI. Dr. Alici received his M.D. and did his residency at the Ege University, Turkey. He earned his Ph.D. in 2006 at KI.
Dr. Alici’s main research interests are novel approaches to generating universal cells including allogeneic NK cells, multiple myeloma, lentiviral and retroviral gene transfer, stem cell transplantation and immunology.
Dr. Alici participated in the planning and design of the first clinical study with gene-modified cells in Sweden and authored the final publication. Additionally, he was also responsible for the first-in-man autologous NK cell therapy clinical trial that was classified as advanced therapy medicinal product use. Dr. Alici is affiliated with VyGen-Bio.

Hans-Gustaf Ljunggren M.D., PhD.
Professor Ljunggren is the former Dean of Research at Karolinska Institutet and founder of the Center for Infectious Medicine, Department of Medicine, Karolinska Institutet, Karolinska University Hospital and has functioned as Dean of Research at KI. He is a member of the Nobel Assembly at KI, which awards the Nobel Prize in Physiology or Medicine.
READ MORE
Professor Ljunggren earned his medical and doctoral degrees at KI and also serves as Center Director of NextGenNK, an international Competence Center for the development of next-generation NK cell-based cancer immunotherapies based at KI. In 2001, he was appointed Professor of Infection Medicine and Director of the Center for Infectious Medicine (CIM), a Strategic Research Center at the Department of Medicine, and has authored over 300 articles within the fields of immunology, infectious diseases and cancer and been cited more than 40,000 times.
Professor Ljunggren has been a member of the organizing or scientific committees of numerous international conferences and has had multiple national and international assignments, involving external research evaluations and participation in international advisory boards. Dr. Ljunggren is affiliated with VyGen-Bio.

Arnika Kathleen Wagner PhD., Assistant Professor
Since 2019, Dr. Wagner has been an assistant professor at the KI’s Dept. of Medicine Huddinge, studying NK cells in immunotherapy in Multiple Myeloma.
READ MORE
Dr. Wagner is particularly interested in advancing the use of genetically modified NK cells in different immunotherapeutic approaches.
Dr. Wagner earned her M.Sc. in 2008 from the University of Lübeck, Germany and conducted her Ph.D. studies under the supervision of Klas Kärre at the Dept of Microbiology, Tumor and Cell Biology, at KI, where her research focused on NK cells in mouse models for immunotherapy and studied the crosstalk of NK cells with other immune cells. Dr. Wagner is affiliated with VyGen-Bio.